Income Statement Thermo Fisher Scientific, Inc.
Equities
TMO
US8835561023
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 472.80 USD | -1.91% |
|
-4.00% | -18.41% |
| 06-03 | Thermo Fisher Scientific Shares Fall After HSBC Downgrade | MT |
| 06-03 | HSBC Downgrades Thermo Fisher Scientific to Hold From Buy, Adjusts Price Target to $540 From $670 | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 39.21B | 44.92B | 42.86B | 42.88B | 44.56B | |||||
Other Revenues, Total | - | - | - | - | -1M | |||||
Total Revenues | 39.21B | 44.92B | 42.86B | 42.88B | 44.56B | |||||
Cost of Goods Sold, Total | 19.57B | 25.92B | 25.74B | 25.13B | 26.25B | |||||
Gross Profit | 19.64B | 19B | 17.11B | 17.75B | 18.3B | |||||
Selling General & Admin Expenses, Total | 8B | 8.94B | 8.38B | 8.6B | 8.53B | |||||
R&D Expenses | 1.41B | 1.47B | 1.34B | 1.39B | 1.4B | |||||
Other Operating Expenses | 3M | - | 1M | 30M | 20M | |||||
Other Operating Expenses, Total | 9.41B | 10.41B | 9.72B | 10.02B | 9.94B | |||||
Operating Income | 10.23B | 8.59B | 7.39B | 7.73B | 8.36B | |||||
Interest Expense, Total | -536M | -726M | -1.38B | -1.39B | -1.42B | |||||
Interest And Investment Income | 43M | 272M | 879M | 1.08B | 993M | |||||
Net Interest Expenses | -493M | -454M | -496M | -312M | -426M | |||||
Income (Loss) On Equity Invest. | -4M | -172M | -59M | -42M | -41M | |||||
Currency Exchange Gains (Loss) | 162M | 102M | -29M | -16M | 66M | |||||
Other Non Operating Income (Expenses) | -161M | -35M | 5M | 5M | -89M | |||||
EBT, Excl. Unusual Items | 9.73B | 8.03B | 6.82B | 7.37B | 7.87B | |||||
Restructuring Charges | -37M | -95M | -233M | -104M | -197M | |||||
Merger & Related Restructuring Charges | -35M | - | - | - | -4M | |||||
Gain (Loss) On Sale Of Investments | 66M | -161M | -46M | 21M | -38M | |||||
Gain (Loss) On Sale Of Assets | - | 14M | - | - | - | |||||
Asset Writedown | -122M | -60M | -219M | -252M | -94M | |||||
Legal Settlements | - | - | -19M | - | - | |||||
Other Unusual Items | -767M | -63M | -59M | -39M | -267M | |||||
EBT, Incl. Unusual Items | 8.84B | 7.66B | 6.24B | 7B | 7.27B | |||||
Income Tax Expense | 1.11B | 703M | 284M | 657M | 547M | |||||
Earnings From Continuing Operations | 7.73B | 6.96B | 5.96B | 6.34B | 6.72B | |||||
Earnings Of Discontinued Operations | - | - | - | - | - | |||||
Net Income to Company | 7.73B | 6.96B | 5.96B | 6.34B | 6.72B | |||||
Minority Interest | -3M | -10M | 40M | -3M | -17M | |||||
Net Income - (IS) | 7.72B | 6.95B | 6B | 6.34B | 6.7B | |||||
Net Income to Common Incl Extra Items | 7.72B | 6.95B | 6B | 6.34B | 6.7B | |||||
Net Income to Common Excl. Extra Items | 7.72B | 6.95B | 6B | 6.34B | 6.7B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 19.61 | 17.73 | 15.53 | 16.58 | 17.78 | |||||
Basic EPS - Continuing Operations | 19.61 | 17.73 | 15.53 | 16.58 | 17.78 | |||||
Basic Weighted Average Shares Outstanding | 394M | 392M | 386M | 382M | 377M | |||||
Net EPS - Diluted | 19.46 | 17.63 | 15.45 | 16.53 | 17.74 | |||||
Diluted EPS - Continuing Operations | 19.46 | 17.63 | 15.45 | 16.53 | 17.74 | |||||
Diluted Weighted Average Shares Outstanding | 397M | 394M | 388M | 383M | 378M | |||||
Normalized Basic EPS | 15.43 | 12.77 | 11.14 | 12.05 | 13 | |||||
Normalized Diluted EPS | 15.31 | 12.71 | 11.08 | 12.02 | 12.96 | |||||
Dividend Per Share | 1.04 | 1.2 | 1.4 | 1.56 | 1.72 | |||||
Payout Ratio | 5.11 | 6.55 | 8.72 | 9.2 | 9.49 | |||||
American Depositary Receipts Ratio (ADR) | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |||||
Supplemental Items | ||||||||||
EBITDA | 12.82B | 11.97B | 10.8B | 10.84B | 11.14B | |||||
EBITA | 11.99B | 10.98B | 9.73B | 9.69B | 10.09B | |||||
EBIT | 10.23B | 8.59B | 7.39B | 7.73B | 8.36B | |||||
EBITDAR | 13.14B | 12.43B | 11.27B | 11.31B | 11.64B | |||||
Total Revenues (As Reported) | 39.21B | 44.92B | 42.86B | 42.88B | 44.56B | |||||
Effective Tax Rate - (Ratio) | 12.55 | 9.17 | 4.55 | 9.39 | 7.53 | |||||
Current Domestic Taxes | 606M | 1.07B | 378M | 691M | 528M | |||||
Current Foreign Taxes | 1.15B | 633M | 1.21B | 1.18B | 658M | |||||
Total Current Taxes | 1.75B | 1.7B | 1.58B | 1.87B | 1.19B | |||||
Deferred Domestic Taxes | -246M | -683M | -653M | -1.14B | -419M | |||||
Deferred Foreign Taxes | -399M | -314M | -647M | -72M | -221M | |||||
Total Deferred Taxes | -645M | -997M | -1.3B | -1.21B | -640M | |||||
Normalized Net Income | 6.08B | 5.01B | 4.3B | 4.6B | 4.9B | |||||
Non-Cash Pension Expense | -6M | -16M | -5M | 0 | 3M | |||||
Supplemental Operating Expense Items | ||||||||||
Research And Development Expense From Footnotes | 1.41B | 1.47B | 1.34B | 1.39B | 1.4B | |||||
Net Rental Expense, Total | 320M | 460M | 470M | 468M | 497M | |||||
Imputed Operating Lease Interest Expense | 46.57M | 73.7M | 142M | 150M | 153M | |||||
Imputed Operating Lease Depreciation | 273M | 386M | 328M | 318M | 344M | |||||
Stock-Based Comp., Other (Total) | 230M | 307M | 278M | 301M | 310M | |||||
Total Stock-Based Compensation | 230M | 307M | 278M | 301M | 310M |
- Stock Market
- Equities
- TMO Stock
- Financials Thermo Fisher Scientific, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















